Comment from Jason Hsu

Summary: The commenter, representing a group of researchers/academics, suggests specific technical clarifications to the draft guidance regarding Type I error rate control. They argue that the guidance should explicitly reference the "Error Rate per Family" (ERpF) to clarify how the FDA controls incorrect regulatory approvals across multiple studies and platform trials.